

1 **Title:**

2 Hypothalamic structure and function in Alzheimer's disease and Lewy-body dementia: a  
3 systematic review and meta-analysis

4 **Authors:**

5 Axel AS Laurell<sup>1,2,\*</sup>, Sita N Shah<sup>1,2</sup>, Masoud Rahmati<sup>3,4,5</sup>, John T O'Brien<sup>1,2</sup>, Benjamin R  
6 Underwood<sup>1,2</sup>

7 **Affiliations:**

8 <sup>1</sup>Department of Psychiatry, University of Cambridge School of Clinical Medicine, Level E4,  
9 Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, United Kingdom.

10 <sup>2</sup>Cambridgeshire and Peterborough NHS Foundation Trust, Windsor Unit, Fulbourn Hospital,  
11 Cambridge CB21 5EF

12 <sup>3</sup>CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University,  
13 Marseille, France

14 <sup>4</sup>Department of Physical Education and Sport Sciences, Faculty of Literature and Human  
15 Sciences, Lorestan University, Khoramabad, Iran,

16 <sup>5</sup>Department of Physical Education and Sport Sciences, Faculty of Literature and  
17 Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran

18 **\*Corresponding author:**

19 al2087@cam.ac.uk

20

21 **Abstract**

22 Background

23 Changes to sleep, weight, and endocrine function are common in Alzheimer's disease (AD)  
24 and Lewy-body dementia (LBD). The cause of these is not known, but they may be related  
25 to hypothalamic neurodegeneration.

26 Methods

27 We performed a systematic search of MEDLINE and EMBASE of studies using structural  
28 magnetic resonance imaging to examine hypothalamic volume in people with AD or LBD.  
29 The Newcastle-Ottawa scale was used to assess the risk of bias. A random-effects meta-  
30 analysis was conducted using the standardised mean difference (SMD) in hypothalamic  
31 volume as the effect measure, and a narrative synthesis was used to examine the  
32 relationship between hypothalamic volume and sleep, eating, and endocrine function.

33 Results

34 We identified 6542 articles which resulted in 12 included studies, most which had a low to  
35 moderate risk of bias. The meta-analysis included 454 people with mild-moderate AD (Mini-  
36 Mental State (MMSE) range: 19.2-26.1) and 715 controls. We found that people with AD had  
37 a significantly smaller hypothalamus (pooled SMD: -0.49,  $t=-3.47$ ,  $p=0.018$ , 95%CI: -0.86 to -  
38 0.13). There was significant heterogeneity of a moderate degree ( $\text{Tau}^2=0.0665$ ,  
39 95%CI:0.005-0.8090;  $I^2=67\%$ , 95%CI:21.5%-86.1%;  $Q=15.16$ ,  $p<0.01$ ), but no evidence of  
40 publication bias. Only one study examined people with LBD, finding qualitative evidence of  
41 lower hypothalamic volume compared to controls. Hypothalamic volume loss in AD was  
42 more marked in men and may be associated with plasma levels of sex hormones and  
43 decreased bone mineral density.

44 Conclusion

45 Reduced hypothalamic volume is seen early in AD and LBD and this may influence  
46 endocrine function. A better understanding of hypothalamic degeneration in dementia may  
47 help elucidate how pathology relates to symptoms in AD and LBD and reveal new targets for  
48 intervention.

## 49 **1.0 Introduction**

50 Alzheimer's disease (AD) and Lewy-body dementia (LBD), consisting of Dementia with Lewy  
51 Bodies (DLB) and Parkinson's disease dementia (PDD), are two of the most common  
52 causes of dementia (Goodman et al., 2017). In addition to the well-described cognitive  
53 impairment associated with these illnesses, many people with AD and LBD develop other  
54 symptoms including sleep disturbances (Koren et al., 2023), loss of appetite (Soysal et al.,  
55 2021), endocrine (Popp et al., 2015) and metabolic dysfunction (Xie et al., 2023). The  
56 causes of these are poorly understood, but may be related to neurodegenerative changes in  
57 specific brain regions that are involved in the control of these physiological processes. The  
58 hypothalamus is a small grey matter structure which consists of more than 12 different nuclei  
59 that are responsible for regulating a range of homeostatic, metabolic and autonomic  
60 functions, including appetite and the 24-hour circadian rhythm (Ishii and Iadecola, 2015).  
61 The hypothalamus is also the main regulator of many of the body's endocrine processes via  
62 pathways such as the hypothalamic-pituitary-adrenal (HPA) axis, the hypothalamic-pituitary-  
63 gonadal (HPG) axis, the hypothalamic-pituitary-thyroid axis and the hypothalamic-pituitary-  
64 somatotrophic axis. Changes in plasma levels of glucocorticoids (Huang et al., 2009), sex  
65 hormones (Livingston et al., 2024), thyroid hormones (Tang et al., 2021), and somatotrophic  
66 hormones (Westwood et al., 2014) are associated with increased risk of developing  
67 dementia and metabolic conditions such as osteoporosis, indicating that hypothalamic  
68 signalling pathways may be involved (Niwczyk et al., 2023).

69 Although, neuropathological studies have established that the hypothalamus is affected by  
70 LBD (Braak et al., 2003) and AD pathology (Braak and Braak, 1991), it is not clear if this is  
71 an early or late feature of these conditions or whether there is a functional impact of  
72 neurodegeneration in this structure. These are important questions as it is possible that  
73 hypothalamic neuronal loss could drive global pathology, for example through changes in  
74 sleep, and any impact on the endocrine system could be related to AD symptomatology. The  
75 hypothalamus is a promising drug target due to its diverse and well understood receptor  
76 profile so understanding its role in disease might quickly translate into treatment (Romanov  
77 et al. 2017).

78 One challenge of studying the hypothalamus *in vivo* using magnetic resonance imaging  
79 (MRI) is its small size and poor tissue contrast, and traditional methods of manual  
80 segmentation are time-consuming and requires expert knowledge of neuroanatomy.  
81 Recently, several automatic segmentation pipelines have been developed which allows the  
82 hypothalamus to be segmented into subregions (Billot et al., 2020; Chang et al., 2022). This  
83 allows the hypothalamic volume to be evaluated in larger cohort studies to assess whether

84 the hypothalamus is affected early in dementia. It also makes it possible to test the  
85 hypothesis that volumetric changes in specific hypothalamic subunits are associated with  
86 specific signs and symptoms. The primary outcome of this meta-analysis was to assess  
87 whether there was evidence for any structural changes in the hypothalamus in people with  
88 AD or LBD using *in vivo* structural MRI. The secondary objective was to assess whether  
89 there was an association between the structure of the hypothalamus and dementia  
90 symptoms including changes to weight, sleep and endocrine function.

91

## 92 **2.0 Methods**

93 The protocol for the review was preregistered on PROSPERO  
94 (<https://www.crd.york.ac.uk/prospero/>, registration number: CRD42024547743) and the  
95 manuscript was produced using the PRISMA guidelines (Page et al., 2021).

### 96 2.1 Search strategy

97 We performed a systematic search of MEDLINE and EMBASE from inception to 15<sup>th</sup> May  
98 2024 using the Ovid platform, to identify studies of people with AD or LBD which examined  
99 the structure of the hypothalamus. The search string used was (hypothal\* AND (MRI or  
100 magnetic resonance imaging) AND (Alzheimer\* OR DLB OR Lewy OR LBD OR Parkinson\*  
101 disease dementia OR PDD)). Filters were used to limit the search to human studies in  
102 English, using people aged 18 or over, published in “journal” or “report”, and to remove  
103 conference abstracts and duplicates.

### 104 2.2 Eligibility criteria

105 We only included studies using structural MRI imaging *in vivo* in humans, assessing the  
106 volume of the hypothalamus, and excluded neuropathological studies and studies of  
107 animals. Case studies and series, reviews, meta-analyses, conference abstracts and non-  
108 peer reviewed material were also excluded.

### 109 2.3 Data extraction and quality assessment

110 Two authors (AASL and SNS) worked independently to screen the titles, abstracts and full-  
111 texts to identify articles for inclusion using the online platform Rayyan (rayyan.ai). The  
112 reference lists of all included studies were reviewed to identify any further studies meeting  
113 the inclusion criteria. Any disagreements were resolved by discussion with a third reviewer  
114 (BRU). The Newcastle-Ottawa scale for case-control studies was used to assess the quality  
115 and risk of bias of all included studies (Wells et al., 2021). This tool assesses non-  
116 randomised studies using three domains (selection, comparability and exposure), to allow

117 studies to be stratified as being of “low” (8-9 points), “moderate” (6-7 points) or “high” ( $\leq 5$   
118 points) risk of bias. Data was extracted from the included studies using pre-defined tables.  
119 For the meta-analysis, this included the mean hypothalamic volume, standard deviation and  
120 sample size of the AD and control groups. For the narrative synthesis, this included any  
121 qualitative evidence of group difference in hypothalamic volume (from whole brain voxel-  
122 based morphometry (VBM) studies), and associations between hypothalamic volume, weight  
123 or appetite, sleep and endocrine function. Two studies met the inclusion criteria but did not  
124 report sufficient quantitative data to be included in the meta-analysis. After contacting the  
125 authors of both studies, one was able to provide the necessary additional data (Ofori et al.,  
126 2024), whereas the other study was included in the narrative synthesis but not the meta-  
127 analysis (Billot et al., 2020).

## 128 2.4 Statistical analysis

129 A random-effects meta-analysis was conducted using the meta package in R studio (version  
130 2021.09.0) to determine whether there was a difference in hypothalamic volume between  
131 dementia and controls. The standardised mean difference (SMD, Cohen’s d) between AD  
132 and controls was calculated to homogenise the data, since studies reported volumetric  
133 changes in the hypothalamus in different units ( $\text{mm}^3$  or % of intracranial volume). Hedges’ g  
134 was then calculated and used as the effect size in the meta-analysis. This applies a small-  
135 sample correction factor to the Cohen’s d, since the effect size can be overestimated in  
136 studies with small sample sizes. A Hedges’ g of 0.2 indicates a small effect, while 0.5 and 0.8  
137 indicates a medium and large effect respectively. The percentage difference in volume for  
138 each study was also calculated and averaged across the number of included studies since  
139 this may be more easily interpretable. Heterogeneity ( $\text{Tau}^2$ ) was estimated using the  
140 restricted maximum likelihood procedure, and Knapp-Hartung adjustment was applied to  
141 control for the uncertainty of the between-study heterogeneity. The Q statistic was calculated  
142 to assess whether the level of between-study heterogeneity was significant and the  $I^2$   
143 statistic was used to quantify this (25%= low, 50%=moderate, 75%=substantial) (Higgins and  
144 Thompson, 2002). Publication bias was assessed by Egger’s regression test, and by  
145 inspection of the funnel plot. A narrative synthesis strategy was applied to assess whether  
146 there was a relationship between structural changes and non-cognitive symptoms of  
147 dementia.

148

## 149 **3.0 Results**

150 The article selection process is displayed in Figure 1. The search identified the titles and  
151 abstracts of 6542 articles which were screened to identify 63 articles for full-text review after

152 being marked for further consideration by at least one author. A list of the articles excluded  
153 after full-text review is available in supplementary Table S1. Two articles were identified from  
154 screening the reference lists of included studies and relevant review articles. This resulted in  
155 the inclusion of 6 articles which provided quantitative measurements of hypothalamic volume  
156 in AD that could be extracted for the meta-analysis (Grundman et al., 1996; Callen et al.,  
157 2001; Loskutova et al., 2010; Ahmed et al., 2015; Chang et al., 2023; Ofori et al., 2024). A  
158 further 6 studies reported qualitative changes in hypothalamic volume as part of whole brain  
159 VBM, and/or associations between hypothalamic volume and clinical symptoms, and these  
160 were included in the secondary narrative synthesis (Baron et al., 2001; Callen et al., 2004;  
161 Whitwell et al., 2007; Hall et al., 2008; Kim et al., 2016; Billot et al., 2020). There was only  
162 one study examining people with DLB using VBM, and no studies which included people  
163 with PDD. The included studies had mostly (83%) a low, or moderate risk of bias, with only  
164 two studies rated as high risk of bias. The extracted data is displayed in Table 1.

165 One study which initially appeared to meet the inclusion criteria, demonstrated that the  
166 volume of the mamillary bodies, which is part of the posterior hypothalamus, was reduced in  
167 people with AD compared to controls (Copenhaver et al., 2006). This was not included in the  
168 data synthesis since it did not provide a volumetric measure for the full hypothalamus,  
169 although it is consistent with the findings of the included studies.

### 170 3.1 Hypothalamic volume in AD and DLB versus controls

171 The results of the random-effects meta-analysis is displayed in Figure 2, which includes data  
172 from a total of 454 people with mild-moderate AD (MMSE range: 19.2-26.1) and 715 healthy  
173 controls. The pooled standardised mean difference was -0.49 ( $t=-3.47$ ,  $p=0.018$ , 95%CI: -  
174 0.86 to -0.13), indicating that people with AD had a significantly smaller hypothalamus, a  
175 difference which can be considered to be of a small-to-medium effect size. The between-  
176 study heterogeneity variance was estimated at  $\text{Tau}^2 = 0.0665$  (95%CI: 0.005-0.8090),  $I^2 =$   
177 67% (95%CI: 21.5%-86.1%) and  $Q = 15.16$  ( $p<0.01$ ). This indicates that there was  
178 significant heterogeneity to a moderate degree. On average, the volume of the  
179 hypothalamus was reduced by 10.1% (range: -29.4% to +0.73%) in people with AD  
180 compared to controls. It is important to highlight that no study normalised their findings to the  
181 total grey matter volume, making it difficult to know whether the difference in hypothalamic  
182 volume is over and above the general grey matter atrophy which is seen in AD. The funnel  
183 plot (Figure 3) was largely symmetrical and revealed no signs of publication bias. Egger's  
184 regression test was not significant (intercept -2.16,  $p=0.23$ ).

185 Four studies used whole-brain VBM to provide a qualitative measure of differences in voxels  
186 between people with dementia and controls. Three of these reported grey matter loss in the

187 hypothalamus in people with AD (Baron et al., 2001; Whitwell et al., 2007; Hall et al., 2008),  
188 while one did not report any differences (Kim et al., 2016). The only study using VBM in  
189 people with DLB found grey matter loss in the hypothalamus in DLB compared to controls  
190 (Whitwell et al., 2007). Billot et al. used an automatic segmentation pipeline and found  
191 reduced volumes of all hypothalamic subunits in a large group of people with MCI and AD  
192 compared to healthy controls, but did not provide sufficient volumetric data for inclusion in  
193 the meta-analysis (Billot et al., 2020). The group differences were particularly pronounced in  
194 the anterior-superior, anterior-inferior and the posterior hypothalamic subunits (Cohen's  $d =$   
195 1.16, 0.99, 0.94 respectively), with a relative sparing of the inferior-tubular subunit (Cohen's  
196  $d = 0.34$ ). Although, these studies are consistent with the results of the meta-analysis, there  
197 may be other VBM studies comparing AD to healthy controls which did not specifically  
198 mention the hypothalamus (due to a lack of an effect), and which were therefore not  
199 captured by our search string.

### 200 3.2 Hypothalamic volume in AD versus other neurodegenerative conditions

201 There was no difference in hypothalamic volume in people with AD compared to DLB  
202 (Whitwell et al., 2007), amyotrophic lateral sclerosis (ALS) (Chang et al., 2023), or  
203 Parkinson's disease (Kim et al., 2016). One study found that people with behavioural variant  
204 frontotemporal dementia (bvFTD) had a significantly smaller hypothalamus compared to AD  
205 and controls (Ahmed et al., 2015). However, in this study the hypothalamic volume for the  
206 AD group were not different from the healthy controls, making the group differences difficult  
207 to interpret.

### 208 3.3 Hypothalamus and weight

209 There was no association between hypothalamic volume and body mass index (BMI)  
210 (Grundman et al., 1996; Ahmed et al., 2015; Chang et al., 2023), or with eating habits as  
211 measured by the Cambridge Behavioural Inventory (CBI) or the Appetite and Eating Habits  
212 Questionnaire (APEHQ) (Ahmed et al., 2015). In all three studies the AD group had normal  
213 or slightly raised BMI (mean: 23.8, 26.4, 26.6).

### 214 3.4 Hypothalamus and sleep

215 Higher score on the rapid eye movement (REM) sleep behaviour disorder screening  
216 questionnaire, indicating symptoms of REM sleep behaviour disorder, was associated with  
217 grey matter volume in the hypothalamus, although the association disappeared when  
218 correcting for family-wise error (Kim et al., 2016).

### 219 3.5 Hypothalamus and endocrine function

220 Larger hypothalamic volume was associated with increased bone mineral density in AD  
221 ( $r=0.34$ ,  $p=0.007$ ) (Loskutova et al., 2010). There was no significant association between  
222 hypothalamic volume and plasma levels of appetite-regulating hormones, including leptin,  
223 cholecystokinin, neuropeptide Y, agouti-related peptide, and peptide YY (Ahmed et al.,  
224 2015). Two studies reported that hypothalamic volume was smaller in men than women with  
225 AD (Callen et al., 2004; Ofori et al., 2024), while one study with a high risk of bias found no  
226 effect of sex (Chang et al., 2023). This effect was seen despite the males in the AD group  
227 being at an earlier stage of illness than the females in one of the studies (Callen et al.,  
228 2004). Ofori et al. reported several associations between hypothalamic volume and plasma  
229 levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone and  
230 testosterone, although these were not corrected for multiple comparisons (Ofori et al., 2024).  
231 Increased volume of the inferior-tuberal subunit was weakly associated with levels of FSH  
232 and LH in women with AD ( $R^2=0.11$  (FSH),  $0.12$  (LH)), while no associations were found in  
233 men with AD. In people with mild cognitive impairment (MCI), there were weak associations  
234 between FSH, LH, progesterone, and testosterone and the volume of all hypothalamic  
235 subunits apart from the anterior-inferior subunit ( $R^2=0.05-0.08$ ). In healthy controls there  
236 were associations between the inferior-tuberal subunit and progesterone ( $R^2=0.18$  (men)  
237 and  $R^2=0.38$  (women)), inferior-tuberal subunit and testosterone ( $R^2=0.20$  women only),  
238 superior-tuberal subunit and testosterone ( $R^2=0.20$  men only), and posterior hypothalamus  
239 and LH ( $R^2=0.21$  men and  $R^2=0.21$  women). This suggests that the association between  
240 hypothalamic volume and plasma sex hormones weakens with worsened cognitive status.

241 In summary, multiple studies support that people with AD have a significantly lower  
242 hypothalamic volume than controls. There has been one study in people with DLB with  
243 similar findings. Furthermore, sex may influence hypothalamic volume loss, and decreased  
244 hypothalamic volume may be associated with lower bone mineral density and plasma levels  
245 of sex hormones although this needs further confirmation. No significant associations were  
246 found with BMI or sleep.

247

#### 248 **4.0 Discussion**

249 We found that people with AD have a smaller hypothalamus compared to healthy controls,  
250 as measured by *in vivo* volumetric MRI imaging. Most of the studies investigated people with  
251 mild-to-moderate AD, indicating that hypothalamic changes are present early in the clinical  
252 course. A previous narrative review has described the role of the hypothalamus in AD,  
253 although it only included evidence from 7 volumetric MRI studies (Ishii and Iadecola, 2015).  
254 Here, we use both a meta-analytical and narrative approach to synthesise the evidence from



255 12 studies on the structure and function of the hypothalamus in AD and DLB, including  
256 studies which uses recently developed automatic segmentation pipelines (Billot et al., 2020;  
257 Chang et al., 2023; Ofori et al., 2024). The findings are consistent with neuropathological  
258 studies which have found amyloid beta plaques and tau neurofibrillary tangles throughout  
259 the hypothalamus in people with AD, associated with a reduced number of neurons and  
260 morphological changes to organelles (Baloyannis et al., 2015; Braak and Braak, 1991; Lim  
261 et al., 2014). Similarly, Lewy-body pathology has also been found in the hypothalamus of  
262 people with PD, DLB and PDD (Benarroch et al., 2015; Braak et al., 2003; Kasanuki et al.,  
263 2014; Purba et al., 1994).

264 Our results are also consistent with studies using other MRI modalities, which have found  
265 reduced glucose metabolism in the hypothalamus in people with MCI and AD using positron  
266 emission tomography (Cross et al., 2013; Liguori et al., 2017; Nestor et al., 2003). One  
267 study using single-photon emission computed tomography (SPECT) with the tracer  $^{123}\text{I}$ -N- $\omega$ -  
268 fluoropropyl-2 $\beta$ -carbomethoxy-3 $\beta$ -(4-iodophenyl)nortropane ( $^{123}\text{I}$ -FP-CIT) found that people  
269 with DLB had lower serotonergic and/or dopaminergic binding in the hypothalamus  
270 compared with healthy controls (Joling et al., 2019), although other SPECT studies in AD  
271 have failed to demonstrate reduced perfusion in the hypothalamus (Callen et al., 2002, 2004;  
272 Ismail et al., 2008; Lanctot et al., 2004, 2007). This discrepancy is likely a reflection of the  
273 resolution of a SPECT scan being too low to detect any changes in a small structure such as  
274 the hypothalamus without a specific tracer.

275 Studies in other neurodegenerative conditions using both manual and automatic  
276 segmentation protocols have shown that the hypothalamus is smaller in all subtypes of FTD  
277 (9-17% reduction) (Piguet et al., 2011; Ahmed et al., 2015; Bocchetta et al., 2015; Shapiro et  
278 al., 2022; Tse et al., 2023), ALS (22% reduction) (Gorges et al., 2017; Liu et al., 2022; Tse et  
279 al., 2023), in pre-symptomatic carriers of pathogenic FTD-ALS mutations (14% reduction)  
280 (Gorges et al., 2017), and in spinocerebellar ataxia type 3 (3.40% reduction) (Guo et al.,  
281 2022). A VBM study in people with Huntington's disease, suggested that hypothalamic  
282 changes were present 9-15 years before the predicted time of clinical diagnosis (Soneson et  
283 al., 2010), although another study using manual segmentation failed to find any cross-  
284 sectional or longitudinal group differences (Gabery et al., 2015). Studies comparing different  
285 types of dementia do not suggest that the magnitude of volume loss is significantly different  
286 to that seen in AD and DLB. This suggests that the hypothalamus is vulnerable to  
287 neurodegeneration secondary to a range of different pathologies. It is less well understood  
288 whether the loss of volume in the hypothalamus contributes to the development of dementia,  
289 symptomatology or whether this might be amenable to therapeutic intervention.

#### 290 4.1 Hypothalamus and weight

291 Physiologically, appetite is mediated by the hormones leptin and ghrelin, which is secreted  
292 peripherally by adipose tissue and the stomach respectively (Coll et al., 2007). They have  
293 opposing actions on the signalling between the arcuate and the paraventricular nuclei (PVN)  
294 of the hypothalamus, to promote either satiety or increased appetite. Several studies have  
295 assessed this pathway in people with bvFTD, which is commonly associated with binge-  
296 eating, a preference for sucrose and weight gain (Bang et al., 2015). People with bvFTD  
297 overeat despite having a reduced plasma levels of ghrelin and raised leptin, indicating that  
298 there is a central resistance to the effect of these hormones (Woolley et al., 2014). While  
299 people with bvFTD had reduced volume of most hypothalamic subunits, there was a relative  
300 sparing of the inferior-tubular subunit, which contains the arcuate nucleus (Shapiro et al.,  
301 2022; Tse et al., 2023). Furthermore, BMI and eating behaviour, as measured by CBI-R, is  
302 negatively associated with the volume of the anterior-superior, anterior-inferior and posterior  
303 subunits in bvFTD and ALS but not with the inferior-tubular subunit (Gorges et al., 2017; Liu  
304 et al., 2022; Shapiro et al., 2022; Tse et al., 2023). These findings suggests that the  
305 dysregulated appetite in bvFTD is not due to changes in the signalling to the arcuate nucleus  
306 but may instead be due to changes in higher order nuclei, such as the PVN, or in other areas  
307 of the brain. Interestingly, the inferior-tubular subunit was relatively preserved in AD on MRI  
308 imaging (Billot et al., 2020), while neuropathological studies have found that in this nucleus  
309 is either unaffected by pathology (Purba et al., 1994; Saper and German, 1987), or only  
310 affected by pathology in men (Schultz et al., 1996, 1999). This suggests that the arcuate  
311 nucleus may be more resistant to neurodegeneration than other hypothalamic nuclei. Weight  
312 loss is common in both AD and LBD, and this is associated with an increased rate of  
313 mortality and emergency hospitalisation (Soysal et al., 2021). Although there was no  
314 association between appetite or BMI and hypothalamic volume in AD (Grundman et al.,  
315 1996; Ahmed et al., 2015; Chang et al., 2023), this may be due to the normal or slightly  
316 raised BMI of people with AD in these studies. Longitudinal studies are needed to assess  
317 whether weight loss is related to hypothalamic volume in AD or DLB, and whether the  
318 subunit-specific associations are similar to those observed in bvFTD.

#### 319 4.2 Hypothalamus and sleep

320 Sleep disturbance is very common in people living with dementia, with an estimated  
321 prevalence of 24% in Alzheimer's disease and 49% in Lewy body dementia (Koren et al.,  
322 2023). This is a significant issue both for people with dementia and their caregivers where  
323 sleep disturbance is associated with carer stress and need for institutional care. Although the  
324 underlying causes are likely to be multifactorial, it is possible that it involves

325 neurodegeneration of the hypothalamus, since this structure is essential for the regulation of  
326 sleep and wakefulness. Wakefulness is promoted by the histaminergic tuberomammillary  
327 nucleus (TMN) in the posterior hypothalamus, while sleep is promoted by the GABA and  
328 galanin producing neurons of the ventrolateral preoptic nucleus (VLPO) in the anterior  
329 hypothalamus (Saper et al., 2005). The lateral hypothalamus modifies this system through  
330 orexin, which promotes wakefulness, and melanin-concentrating hormone, which promotes  
331 sleep. The 24-hour circadian rhythm is maintained by the suprachiasmatic nucleus (SCN) in  
332 the anterior-inferior hypothalamus, which influences the VLPO and lateral hypothalamus via  
333 its connections to the dorsomedial nucleus. Disruptions to this complex system can cause  
334 sleep-disorders, such in the case of narcolepsy which is characterized by a selective loss of  
335 orexin-producing neurons (Saper et al., 2005). Neuropathological studies have shown that  
336 people with DLB and AD had fewer neurons in the VLPO, SCN and TMN compared to  
337 controls, with associations between the number of neurons and sleep fragmentation,  
338 circadian rhythm and core body temperature (Harper et al., 2008; Fronczek et al., 2012;  
339 Shan et al., 2012; Kasanuki et al., 2014; Lim et al., 2014).

340 In contrast, *in vivo* studies have found that people with MCI and AD have increased levels of  
341 CSF orexin compared with controls, with an association between orexin levels and disrupted  
342 sleep metrics (Liguori et al., 2014, 2016, 2017; Gabelle et al., 2017). In DLB and PDD,  
343 studies have failed to demonstrate any alterations in CSF orexin or any relationship between  
344 orexin and changes in sleep (Yasui et al., 2006; Compta et al., 2009). Furthermore,  
345 treatment with suvorexant, a dual orexin receptor antagonist, have received Food and Drug  
346 Administration (FDA) approval for the treatment of insomnia in Alzheimer's disease after it  
347 was shown to increased total sleep time and reduce waking after sleep onset compared to  
348 placebo (Herring et al., 2020). Suvorexant also acutely reduce the concentration of CSF  
349 amyloid beta and ptau181/tau181 ratio in healthy volunteers (Lucey et al., 2023), and a  
350 longitudinal trial in people at risk of AD is ongoing  
351 (<https://clinicaltrials.gov/study/NCT04629547>). Only two small MRI studies have examined  
352 association between hypothalamus and sleep in AD, finding a significant association  
353 between reduced hypothalamic glucose uptake and increased sleep disturbances (Liguori et  
354 al., 2017), and a trend towards higher REM sleep behaviour disorder score and grey matter  
355 signal on VBM (Kim et al., 2016). Further studies will need to clarify how a reduction in  
356 hypothalamic volume relates to an increase in CSF orexin in AD.

#### 357 4.3 Hypothalamus and endocrine function

358 In addition to maintaining weight, appetite and sleep, the hypothalamus is an important  
359 regulator of several endocrine glands. The HPA axis starts with secretion of corticotrophin-

360 releasing hormone (CRH) from the PVN, which in turn stimulates secretion of  
361 adrenocorticotrophic hormone (ACTH) from the pituitary gland (Ahmad et al., 2019). This  
362 stimulates the secretion of glucocorticoids, such as cortisol, from the adrenal glands which  
363 acts through a negative feedback loop on the hypothalamus and pituitary gland to limit its  
364 own secretion. People with MCI and AD have higher levels of cortisol in plasma and CSF  
365 (Csernansky et al., 2006; Popp et al., 2015), an abnormal dexamethasone suppression test  
366 (O'Brien et al., 1996; Elgh et al., 2006), and increased CRH production in the PVN compared  
367 to healthy controls (Raadsheer et al., 1995). Furthermore, these abnormalities were  
368 associated with higher cerebral amyloid burden (Toledo et al., 2012), increased hippocampal  
369 atrophy (O'Brien et al., 1996; Elgh et al., 2006; Huang et al., 2009), and more rapid decline  
370 on cognitive tests (Huang et al., 2009; Popp et al., 2015), indicating that dysfunction of the  
371 HPA axis may contribute to the progression of the disease.

372 Similarly, the HPG axis consists of gonadotrophin-releasing hormone (GnRH) which is  
373 secreted in a pulsatile manner from the arcuate nucleus of the hypothalamus to stimulate the  
374 secretion of follicle-stimulating hormone (FSH) and luteinising hormone (LH) from the  
375 anterior pituitary gland (Desai et al., 2021). FSH and LH in turn stimulate the release of sex  
376 hormones (testosterone, oestrogens and progesterone) from the gonads which acts through  
377 a negative feedback loop on the hypothalamus and pituitary to regulate the HPG axis. The  
378 decline in plasma levels of neuroprotective sex hormones after menopause, may explain  
379 why AD is more prevalent in women than men (Livingston et al., 2024). However, a meta-  
380 analysis of randomised clinical trials found that hormone replacement therapy with oestrogen  
381 and progesterone after menopause was associated with an increased risk of dementia,  
382 although the timing of initiation, type of formulation and duration of treatment may modify this  
383 risk (Zhou et al., 2021). It is also possible that an increase in GnRH, FSH and LH which also  
384 occurs because of menopause may contribute to the increased risk of AD in women.  
385 Increased levels of FSH and LH, were associated with higher amyloid load, reduced grey  
386 matter volume and hippocampal loss independent of age and menopause status (Nerattini et  
387 al., 2023).

388 A similar pattern is seen in men with AD, who have lower levels of testosterone and higher  
389 levels of FSH and LH compared to controls (Bowen et al., 2000; Butchart et al., 2013). One  
390 ecological study suggests that men who have had treatment with an GnRH agonists for  
391 prostate cancer, had a lower risk of developing AD compared to people who underwent other  
392 procedures (Smith et al., 2018). GnRH agonists work by continuously stimulating the GnRH  
393 receptor in the pituitary which initially causes a spike in FSH, LH and testosterone  
394 production, followed by downregulation of GnRH receptors in the pituitary gland (Desai et al.,  
395 2021). The result is a reduction of FSH, LH and testosterone. The only study using

396 hypothalamic segmentation to investigate the HPG axis in AD, found that the volume of the  
397 inferior tubular subunit, which contains the arcuate nucleus, was associated with plasma  
398 levels of FSH and LH in women, but not men, with AD (Ofori et al., 2024). Furthermore, in  
399 healthy controls and people with MCI, there was a more widespread associations between  
400 hypothalamic volume and plasma levels of FSH, LH, progesterone and testosterone. The  
401 hypothalamus is one of the most highly sexually dimorphic areas of the brain, with healthy  
402 men having a larger hypothalamus than women (Goldstein et al., 2001). Conversely, two  
403 studies in the current review found that men with AD have a smaller hypothalamus than  
404 women (Callen et al., 2004; Ofori et al., 2024), a finding which is consistent with the  
405 neuropathological studies of the arcuate nucleus which is almost exclusively affected by AD  
406 pathology in men but not women (Schultz et al., 1996, 1999). Overall, these studies provide  
407 further indication that hypothalamic pathology may be relevant to explain the sex  
408 discrepancy seen in AD.

409 Hypothalamic pathology in AD may also have an impact on other hormones which are  
410 secreted by the hypothalamus, including growth-hormone releasing hormone (GHRH) and  
411 thyrotropin releasing hormone (TRH). In people with MCI, treatment with GHRH analogues  
412 improves executive function and levels of insulin-like-growth factor 1 (Baker et al., 2012),  
413 and lower plasma levels of this hormone are associated with an increased risk of developing  
414 AD (Westwood et al., 2014). Furthermore, a meta-analysis found that a both an increased  
415 levels of thyroid stimulating hormone (TSH) (indicating primary hypothyroidism) and reduced  
416 TSH levels (indicating primary hyperthyroidism) were associated with an increase in risk of  
417 developing dementia (Tang et al., 2021). Overall, people with established AD have lower  
418 triiodothyronine (T3), but no difference in TSH or thyroxine (T4) compared to controls  
419 (Dolatshahi et al., 2023), while a central pattern of hypothyroidism (reduced TRH, TSH, T3  
420 and T4) may be seen in people with advanced AD (Chen et al., 2013; Yong-Hong et al.,  
421 2013).

422 The new automatic segmentation pipelines will be useful for future studies to determine  
423 whether the abnormalities seen in the HPA, HPG, the hypothalamic-pituitary-thyroid and the  
424 hypothalamic-pituitary-somatotropic (growth hormone) axes in people with AD are related to  
425 hypothalamic pathology. This may have important implications for new treatment targets and  
426 to understand the increased prevalence of osteoporosis in people with AD (Xie et al., 2023).  
427 On study has found that bone mineral density was associated with hypothalamic volume in  
428 AD, but not in healthy controls (Loskutova et al., 2010). Many of the hormones under  
429 hypothalamic control influence bone homeostasis, as seen by the prevalence of  
430 osteoporosis in people with early menopause, and in conditions such as  
431 hyperprolactinaemia, hyperthyroidism and hypocortisolaemia (Niwczyk et al., 2023). In

432 addition to the hormonal route, neuronal signalling from the hypothalamic nuclei also act  
433 directly on osteoblasts through their innervation by the sympathetic nervous system  
434 (Niwczyk et al., 2023). Understanding the causes of osteoporosis in AD is important due to  
435 the significantly higher risk of bone fractures, which in turn is associated with a significant  
436 morbidity and mortality.

#### 437 4.4 Limitations

438 Most of the studies included in this review were small case-control studies, introducing  
439 possible bias, and limiting the generalisability of the conclusions to the general population of  
440 people with AD. The meta-analysis had significant between-study heterogeneity, which is  
441 likely a reflection of the variation in the study population size, MRI acquisition protocol and  
442 analysis protocol. The inclusion of people with different stages of AD may also have  
443 contributed to the heterogeneity, although the range of cognitive scores (MMSE range: 19.2-  
444 26.1) suggests that most people had mild-to-moderate dementia. Despite the heterogeneity  
445 in study design, only two studies (Ahmed et al., 2015; Kim et al., 2016) did not find a  
446 significant difference in hypothalamic volume, while no study reported a larger hypothalamus  
447 in AD. While there was no suggestion of publication bias, the small number of included  
448 studies which could be included in the meta-analysis may have made the funnel plot difficult  
449 to interpret. Finally, due to the absence of longitudinal studies, or studies using AD  
450 biomarkers, it is not possible to make any firm conclusions about the cause of a smaller  
451 hypothalamus, or the changes in volume across the AD disease process.

452

#### 453 5.0 Conclusion

454 In this meta-analysis, we found evidence that the hypothalamus is smaller in people with AD  
455 (-10.1%) compared to healthy controls, as shown by *in vivo* MRI structural imaging. One  
456 study also found qualitative evidence that the hypothalamus is reduced in DLB, but further  
457 studies are required to confirm this finding. Hypothalamic volume is also smaller in other  
458 neurodegenerative conditions, in particular FTD and ALS, suggesting that the hypothalamus  
459 may be vulnerable to neurodegeneration in the context of many different pathological  
460 processes. Hypothalamic volume loss may be greater in men than women, and the arcuate  
461 nuclei may be affected less than others. Finally, a smaller hypothalamus may be associated  
462 with plasma levels of sex hormones and reduced bone mineral density in AD, indicating that  
463 hypothalamic involvement may have specific functional consequences. Further studies will  
464 need to assess how hypothalamic pathology evolves during the disease process in AD and  
465 LBD and its impact on weight, sleep, endocrine function and clinically meaningful  
466 symptomatology.

467

468 **6.0 Funding sources**

469 This research did not receive any specific grant from funding agencies in the public,  
470 commercial, or not-for-profit sectors.

471

472 **7.0 Declaration of interest**

473 AASL's post is funded by a grant from Altos labs and is a member of the National Institute for  
474 Health and Care Research (NIHR) Dementia Portfolio Development Group. This research  
475 was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the  
476 Cambridge Centre for Parkinson's Plus Disorders. The views expressed are those of the  
477 authors and not necessarily those of the NIHR or the Department of Health and Social Care.  
478 Data from this project will also be included as part of a PhD thesis by AASL. BRU is the R&D  
479 director at his trust, CRN lead for dementia for the East of England and national CRN lead  
480 for stratified medicine in dementia. He is the vice-chair of the faculty of old age psychiatry in  
481 the Royal College of Psychiatry. His post is part funded by a generous donation from  
482 Gnodde Goldman Sachs gives. He has served in a paid role on an advisory boards for Lilly  
483 and TauRx.

484

485 **8.0 Data availability**

486 Data is available from the corresponding author upon reasonable request.

487

488 **9.0 References**

- 489 Ahmad, M.H., Fatima, M., Mondal, A.C., 2019. Role of hypothalamic-pituitary-adrenal axis,  
490 hypothalamic-pituitary-gonadal axis and insulin signaling in the pathophysiology of  
491 Alzheimer's disease. *Neuropsychobiology*. 77, 197–205. <https://doi.org/10.1159/000495521>  
492
- 493 Ahmed, R., Latheef, S., Bartley, L., Irish, M., Halliday, G., Kiernan, M., Hodges, J., Piguet,  
494 O., 2015. Eating behavior in frontotemporal dementia: peripheral hormones vs hypothalamic  
495 pathology. *Neurology*. 85, 1310-1317. <https://doi.org/10.1212/WNL.0000000000002018>  
496
- 497 Baker, L.D., Barsness, S.M., Borson, S., Merriam, G.R., Friedman, S.D., Craft, S., Vitiello,  
498 M.V., 2012. Effects of growth hormone–releasing hormone on cognitive function in adults  
499 with mild cognitive impairment and healthy older adults. *Arch. Neurol.* 69, 1420–1429.  
500 <https://doi.org/10.1001/archneurol.2012.1970>  
501
- 502 Baloyannis, S.J., Mavroudis, I., Mitilneos, D., Baloyannis, I.S., Costa, V.G., 2015. The  
503 hypothalamus in Alzheimer's disease: a golgi and electron microscope study. *Am. J.*  
504 *Alzheimers. Dis. Other. Demen.* 30, 478–487. <https://doi.org/10.1177/1533317514556876>  
505
- 506 Bang, J., Spina, S., Miller, B.L., 2015. Frontotemporal dementia. *Lancet*. 386, 1672–1682.  
507 [https://doi.org/10.1016/S0140-6736\(15\)00461-4](https://doi.org/10.1016/S0140-6736(15)00461-4)  
508
- 509 Baron, J.C., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., de la Sayette, V.,  
510 Eustache, F., 2001. In vivo mapping of gray matter loss with voxel-based morphometry in  
511 mild Alzheimer's disease. *Neuroimage*. 14, 298–309.  
512 <https://doi.org/10.1006/nimg.2001.0848>  
513
- 514 Benarroch, E.E., Schmeichel, A.M., Parisi, J.E., Low, P.A., 2015. Histaminergic  
515 tuberomammillary neuron loss in multiple system atrophy and dementia with Lewy bodies.  
516 *Mov. Disord.* 30, 1133–1139. <https://doi.org/10.1002/mds.26287>  
517
- 518 Billot, B., Bocchetta, M., Todd, E., Dalca, A.V., Rohrer, J.D., Iglesias, J.E., 2020. Automated  
519 segmentation of the hypothalamus and associated subunits in brain MRI. *Neuroimage*. 223,  
520 117287. <https://doi.org/10.1016/j.neuroimage.2020.117287>  
521
- 522 Bocchetta, M., Gordon, E., Manning, E., Barnes, J., Cash, D.M., Espak, M., Thomas, D.L.,  
523 Modat, M., Rossor, M.N., Warren, J.D., Ourselin, S., Frisoni, G.B., Rohrer, J.D., 2015.



524 Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal  
525 dementia. *J. Neurol.* 262, 2635–2642. <https://doi.org/10.1007/s00415-015-7885-2>  
526  
527 Bowen, R.L., Isley, J.P., Atkinson, R.L., 2000. An association of elevated serum gonadotropin  
528 concentrations and Alzheimer disease? *J. Neuroendocrinol.* 12, 351–354.  
529 <https://doi.org/10.1046/j.1365-2826.2000.00461.x>  
530  
531 Braak, H., Braak, E., 1991. Neuropathological staging of Alzheimer-related changes. *Acta.*  
532 *Neuropathol.* 82, 239–259. <https://doi.org/10.1007/BF00308809>  
533  
534 Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E., 2003.  
535 Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging.* 24,  
536 197–211. [https://doi.org/10.1016/s0197-4580\(02\)00065-9](https://doi.org/10.1016/s0197-4580(02)00065-9)  
537  
538 Butchart, J., Birch, B., Bassily, R., Wolfe, L., Holmes, C., 2013. Male sex hormones and  
539 systemic inflammation in Alzheimer disease. *Alzheimer. Dis. Assoc. Disord.* 27, 153–156.  
540 <https://doi.org/10.1097/WAD.0b013e318258cd63>  
541  
542 Callen, D., Black, S., Caldwell, C., 2002. Limbic system perfusion in Alzheimer's disease  
543 measured by MRI-coregistered HMPAO SPET. *Eur. J. Nucl. Med. Mol. Imaging.* 29, 899-906.  
544 <https://doi.org/10.1007/s00259-002-0816-3>  
545  
546 Callen, D., Black, S., Caldwell, C., Grady, C., 2004. The influence of sex on limbic volume  
547 and perfusion in AD. *Neurobiol. Aging.* 25, 761-770.  
548 <https://doi.org/10.1016/j.neurobiolaging.2003.08.011>  
549  
550 Callen, D., Black, S., Gao, F., Caldwell, C., Szalai, J., 2001. Beyond the hippocampus: MRI  
551 volumetry confirms widespread limbic atrophy in AD. *Neurology.* 57, 1669-1674.  
552 <https://doi.org/10.1212/wnl.57.9.1669>  
553  
554 Chang, J., Shaw, T.B., Holdom, C.J., McCombe, P.A., Henderson, R.D., Fripp, J., Barth, M.,  
555 Guo, C.C., Ngo, S.T., Steyn, F.J., Alzheimer's Disease Neuroimaging Initiative, 2023. Lower  
556 hypothalamic volume with lower body mass index is associated with shorter survival in  
557 patients with amyotrophic lateral sclerosis. *Eur. J. Neurol.* 30, 57–68.  
558 <https://doi.org/10.1111/ene.15589>  
559

- 560 Chang, J., Steyn, F., Ngo, S., Henderson, R., Guo, C., Bollmann, S., Fripp, J., Barth, M.,  
561 Shaw, T., 2022. Open-source hypothalamic-fornix (OSHy-X) atlases and segmentation tool  
562 for 3T and 7T. *Journal of Open Source Software*. 7, 4368.  
563 <https://doi.org/10.21105/joss.04368>  
564
- 565 Chen, J.-M., Huang, C.-Q., Ai, M., Kuang, L., 2013. Circadian rhythm of TSH levels in  
566 subjects with Alzheimer's disease (AD). *Aging. Clin. Exp. Res.* 25, 153–157.  
567 <https://doi.org/10.1007/s40520-013-0025-x>  
568
- 569 Coll, A.P., Farooqi, I.S., O'Rahilly, S., 2007. The hormonal control of food intake. *Cell*. 129,  
570 251–262. <https://doi.org/10.1016/j.cell.2007.04.001>  
571
- 572 Compta, Y., Santamaria, J., Ratti, L., Tolosa, E., Iranzo, A., Muñoz, E., Valldeoriola, F.,  
573 Casamitjana, R., Ríos, J., Martí, M.J., 2009. Cerebrospinal hypocretin, daytime sleepiness  
574 and sleep architecture in Parkinson's disease dementia. *Brain*. 132, 3308–3317.  
575 <https://doi.org/10.1093/brain/awp263>  
576
- 577 Copenhaver, B.R., Rabin, L.A., Saykin, A.J., Roth, R.M., Wishart, H.A., Flashman, L.A.,  
578 Santulli, R.B., McHugh, T.L., Mamourian, A.C., 2006. The fornix and mammillary bodies in  
579 older adults with Alzheimer's disease, mild cognitive impairment, and cognitive complaints: a  
580 volumetric MRI study. *Psychiatry. Res.* 147, 93–103.  
581 <https://doi.org/10.1016/j.psychresns.2006.01.015>  
582
- 583 Cross, D.J., Anzai, Y., Petrie, E.C., Martin, N., Richards, T.L., Maravilla, K.R., Peskind, E.R.,  
584 Minoshima, S., 2013. Loss of olfactory tract integrity affects cortical metabolism in the brain  
585 and olfactory regions in aging and mild cognitive impairment. *J. Nucl. Med.* 54, 1278–1284.  
586 <https://doi.org/10.2967/jnumed.112.116558>  
587
- 588 Csernansky, J.G., Dong, H., Fagan, A.M., Wang, L., Xiong, C., Holtzman, D.M., Morris, J.C.,  
589 2006. Plasma cortisol and progression of dementia in subjects with Alzheimer-type  
590 dementia. *Am. J. Psychiatry*. 163, 2164–2169. <https://doi.org/10.1176/ajp.2006.163.12.2164>  
591
- 592 Desai, K., McManus, J.M., Sharifi, N., 2021. Hormonal therapy for prostate cancer. *Endocr.*  
593 *Rev.* 42, 354–373. <https://doi.org/10.1210/endrev/bnab002>  
594
- 595 Dolatshahi, M., Salehipour, A., Saghazadeh, A., Sanjari Moghaddam, H., Aghamollaii, V.,  
596 Fotouhi, A., Tafakhori, A., 2023. Thyroid hormone levels in Alzheimer disease: a systematic

597 review and meta-analysis. *Endocrine*. 79, 252–272. [https://doi.org/10.1007/s12020-022-](https://doi.org/10.1007/s12020-022-03190-w)  
598 03190-w  
599  
600 Elgh, E., Lindqvist Astot, A., Fagerlund, M., Eriksson, S., Olsson, T., Näsman, B., 2006.  
601 Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's  
602 disease. *Biol. Psychiatry*. 59, 155–161. <https://doi.org/10.1016/j.biopsych.2005.06.017>  
603  
604 Fronczek, R., van Geest, S., Frölich, M., Overeem, S., Roelandse, F.W.C., Lammers, G.J.,  
605 Swaab, D.F., 2012. Hypocretin (orexin) loss in Alzheimer's disease. *Neurobiol. Aging*. 33,  
606 1642–1650. <https://doi.org/10.1016/j.neurobiolaging.2011.03.014>  
607  
608 Gabelle, A., Jaussent, I., Hirtz, C., Vialaret, J., Navucet, S., Grasselli, C., Robert, P.,  
609 Lehmann, S., Dauvilliers, Y., 2017. Cerebrospinal fluid levels of orexin-A and histamine, and  
610 sleep profile within the Alzheimer process. *Neurobiol. Aging*. 53, 59–66.  
611 <https://doi.org/10.1016/j.neurobiolaging.2017.01.011>  
612  
613 Gabery, S., Georgiou-Karistianis, N., Lundh, S.H., Cheong, R.Y., Churchyard, A., Chua, P.,  
614 Stout, J.C., Egan, G.F., Kirik, D., Petersén, Å., 2015. Volumetric analysis of the  
615 hypothalamus in Huntington disease using 3T MRI: the IMAGE-HD study. *PLoS One*. 10,  
616 e0117593. <https://doi.org/10.1371/journal.pone.0117593>  
617  
618 Goldstein, J.M., Seidman, L.J., Horton, N.J., Makris, N., Kennedy, D.N., Caviness, V.S.,  
619 Faraone, S.V., Tsuang, M.T., 2001. Normal sexual dimorphism of the adult human brain  
620 assessed by in vivo magnetic resonance imaging. *Cereb. Cortex*. 11, 490–497.  
621 <https://doi.org/10.1093/cercor/11.6.490>  
622  
623 Goodman, R.A., Lochner, K.A., Thambisetty, M., Wingo, T.S., Posner, S.F., Ling, S.M., 2017.  
624 Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries,  
625 2011–2013. *Alzheimers Dement*. 13, 28–37. <https://doi.org/10.1016/j.jalz.2016.04.002>  
626  
627 Gorges, M., Vercruysse, P., Müller, H.-P., Huppertz, H.-J., Rosenbohm, A., Nagel, G., Weydt,  
628 P., Petersén, Å., Ludolph, A.C., Kassubek, J., Dupuis, L., 2017. Hypothalamic atrophy is  
629 related to body mass index and age at onset in amyotrophic lateral sclerosis. *J. Neurol.*  
630 *Neurosurg. Psychiatry*. 88, 1033–1041. <https://doi.org/10.1136/jnnp-2017-315795>  
631

- 632 Grundman, M., Corey-Bloom, J., Jernigan, T., Archibald, S., Thal, L., 1996. Low body weight  
633 in Alzheimer's disease is associated with mesial temporal cortex atrophy. *Neurology*. 46,  
634 1585-1591. <https://doi.org/10.1212/wnl.46.6.1585>  
635
- 636 Guo, J., Jiang, Z., Biswal, B.B., Zhou, B., Xie, D., Gao, Q., Sheng, W., Chen, Hui, Zhang, Y.,  
637 Fan, Y., Wang, J., Liu, C., Chen, H., 2022. Hypothalamic atrophy, expanded CAG repeat,  
638 and low body mass index in spinocerebellar ataxia type 3. *Mov. Disord.* 37, 1541–1546.  
639 <https://doi.org/10.1002/mds.29029>  
640
- 641 Hall, A.M., Moore, R.Y., Lopez, O.L., Kuller, L., Becker, J.T., 2008. Basal forebrain atrophy is  
642 a presymptomatic marker for Alzheimer's disease. *Alzheimers. Dement.* 4, 271–279.  
643 <https://doi.org/10.1016/j.jalz.2008.04.005>  
644
- 645 Harper, D.G., Stopa, E.G., Kuo-Leblanc, V., McKee, A.C., Asayama, K., Volicer, L., Kowall,  
646 N., Satlin, A., 2008. Dorsomedial SCN neuronal subpopulations subserve different functions  
647 in human dementia. *Brain*. 131, 1609–1617. <https://doi.org/10.1093/brain/awn049>  
648
- 649 Herring, W.J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J.,  
650 Lines, C., Michelson, D., 2020. Polysomnographic assessment of suvorexant in patients with  
651 probable Alzheimer's disease dementia and insomnia: a randomized trial. *Alzheimers.*  
652 *Dement.* 16, 541–551. <https://doi.org/10.1002/alz.12035>  
653
- 654 Higgins, J.P.T., Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis. *Stat.*  
655 *Med.* 21, 1539–1558. <https://doi.org/10.1002/sim.1186>  
656
- 657 Huang, C.-W., Lui, C.-C., Chang, W.-N., Lu, C.-H., Wang, Y.-L., Chang, C.-C., 2009.  
658 Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in  
659 Alzheimer's disease. *J. Clin. Neurosci.* 16, 1283–1286.  
660 <https://doi.org/10.1016/j.jocn.2008.12.026>  
661
- 662 Ishii, M., Iadecola, C., 2015. Metabolic and non-cognitive manifestations of Alzheimer's  
663 disease: the hypothalamus as both culprit and target of pathology. *Cell. Metab.* 22, 761–776.  
664 <https://doi.org/10.1016/j.cmet.2015.08.016>  
665
- 666 Ismail, Z., Herrmann, N., Rothenburg, L., Cotter, A., Leibovitch, F., Rafi-Tari, S., Black, S.,  
667 Lanctot, K., 2008. A functional neuroimaging study of appetite loss in Alzheimer's disease. *J.*  
668 *Neurol. Sci.* 271, 97-103. <https://doi.org/10.1016/j.jns.2008.03.023>

669

670 Joling, M., Vriend, C., Raijmakers, P.G.H.M., van der Zande, J.J., Lemstra, A.W., Berendse,  
671 H.W., Booij, J., van den Heuvel, O.A., 2019. Striatal DAT and extrastriatal SERT binding in  
672 early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy  
673 controls: an 123I-FP-CIT SPECT study. *Neuroimage. Clin.* 22, 101755.

674 <https://doi.org/10.1016/j.nicl.2019.101755>

675

676 Kasanuki, K., Iseki, E., Kondo, D., Fujishiro, H., Minegishi, M., Sato, K., Katsuse, O., Hino,  
677 H., Kosaka, K., Arai, H., 2014. Neuropathological investigation of hypocretin expression in  
678 brains of dementia with Lewy bodies. *Neurosci. Lett.* 569, 68–73.

679 <https://doi.org/10.1016/j.neulet.2014.03.020>

680

681 Kim, H.-J., Im, H., Kim, J., Han, J.-Y., De Leon, M., Deshpande, A., Moon, W.-J., 2016. Brain  
682 atrophy of secondary REM-sleep behavior disorder in neurodegenerative disease. *J.*  
683 *Alzheimers. Dis.* 52, 1101-1109. <https://doi.org/10.3233/JAD-151197>

684

685 Koren, T., Fisher, E., Webster, L., Livingston, G., Rapaport, P., 2023. Prevalence of sleep  
686 disturbances in people with dementia living in the community: a systematic review and meta-  
687 analysis. *Ageing. Res. Rev.* 83, 101782. <https://doi.org/10.1016/j.arr.2022.101782>

688

689 Lanctot, K., Herrmann, N., Nadkarni, N., Leibovitch, F., Caldwell, C., Black, S., 2004. Medial  
690 Temporal Hypoperfusion and Aggression in Alzheimer Disease. *Arch. Neurol.* 61, 1731-1737.

691 <https://doi.org/10.1001/archneur.61.11.1731>

692

693 Lanctot, K., Moosa, S., Herrmann, N., Leibovitch, F., Rothenburg, L., Cotter, A., Black, S.,  
694 2007. A SPECT study of apathy in Alzheimer's disease. *Dement. Geriatr. Cogn. Disord.* 24,  
695 65-72. <https://doi.org/10.1159/000103633>

696

697 Liguori, C., Chiaravalloti, A., Nuccetelli, M., Izzi, F., Sancesario, G., Cimini, A., Bernardini, S.,  
698 Schillaci, O., Mercuri, N., Fabio, P., 2017. Hypothalamic dysfunction is related to sleep  
699 impairment and CSF biomarkers in Alzheimer's disease. *J. Neurol.* 264, 2215-2223.

700 <https://doi.org/10.1007/s00415-017-8613-x>

701

702 Liguori, C., Nuccetelli, M., Izzi, F., Sancesario, G., Romigi, A., Martorana, A., Amoroso, C.,  
703 Bernardini, S., Marciani, M.G., Mercuri, N.B., Placidi, F., 2016. Rapid eye movement sleep  
704 disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-

705 fluid levels in mild cognitive impairment due to Alzheimer's disease. *Neurobiol. Aging*. 40,  
706 120–126. <https://doi.org/10.1016/j.neurobiolaging.2016.01.007>  
707  
708 Liguori, C., Romigi, A., Nuccetelli, M., Zannino, S., Sancesario, G., Martorana, A., Albanese,  
709 M., Mercuri, N.B., Izzì, F., Bernardini, S., Nitti, A., Sancesario, G.M., Sica, F., Marciani, M.G.,  
710 Placidi, F., 2014. Orexinergic system dysregulation, sleep impairment, and cognitive decline  
711 in Alzheimer disease. *JAMA. Neurol.* 71, 1498–1505.  
712 <https://doi.org/10.1001/jamaneurol.2014.2510>  
713  
714 Lim, A.S.P., Ellison, B.A., Wang, J.L., Yu, L., Schneider, J.A., Buchman, A.S., Bennett, D.A.,  
715 Saper, C.B., 2014. Sleep is related to neuron numbers in the ventrolateral  
716 preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. *Brain*.  
717 137, 2847–2861. <https://doi.org/10.1093/brain/awu222>  
718  
719 Liu, S., Ren, Q., Gong, G., Sun, Y., Zhao, B., Ma, X., Zhang, N., Zhong, S., Lin, Y., Wang,  
720 W., Zheng, R., Yu, X., Yun, Y., Zhang, D., Shao, K., Lin, P., Yuan, Y., Dai, T., Zhang, Y., Li, L.,  
721 Li, W., Zhao, Y., Shan, P., Meng, X., Yan, C., 2022. Hypothalamic subregion abnormalities  
722 are related to body mass index in patients with sporadic amyotrophic lateral sclerosis. *J.*  
723 *Neurol.* 269, 2980–2988. <https://doi.org/10.1007/s00415-021-10900-3>  
724  
725 Livingston, G., Huntley, J., Liu, K.Y., Costafreda, S.G., Selbæk, G., Alladi, S., Ames, D.,  
726 Banerjee, S., Burns, A., Brayne, C., Fox, N.C., Ferri, C.P., Gitlin, L.N., Howard, R., Kales,  
727 H.C., Kivimäki, M., Larson, E.B., Nakasujja, N., Rockwood, K., Samus, Q., Shirai, K., Singh-  
728 Manoux, A., Schneider, L.S., Walsh, S., Yao, Y., Sommerlad, A., Mukadam, N., 2024.  
729 Dementia prevention, intervention, and care: 2024 report of the Lancet standing  
730 Commission. *Lancet*. 404, 572-628. [https://doi.org/10.1016/S0140-6736\(24\)01296-0](https://doi.org/10.1016/S0140-6736(24)01296-0)  
731  
732 Loskutova, N., Honea, R., Brooks, W., Burns, J., 2010. Reduced limbic and hypothalamic  
733 volumes correlate with bone density in early Alzheimer's disease. *J Alzheimers. Dis.* 20, 313-  
734 322. <https://doi.org/10.3233/JAD-2010-1364>  
735  
736 Lucey, B.P., Liu, H., Toedebusch, C.D., Freund, D., Redrick, T., Chahin, S.L., Mawuenyega,  
737 K.G., Bollinger, J.G., Ovod, V., Barthélemy, N.R., Bateman, R.J., 2023. Suvorexant acutely  
738 decreases tau phosphorylation and A $\beta$  in the human CNS. *Ann. Neurol.* 94, 27–40.  
739 <https://doi.org/10.1002/ana.26641>  
740

- 741 Nerattini, M., Rubino, F., Jett, S., Andy, C., Boneu, C., Zarate, C., Carlton, C., Loeb-Zeitlin,  
742 S., Havryliuk, Y., Pahlajani, S., Williams, S., Berti, V., Christos, P., Fink, M., Dyke, J.P.,  
743 Brinton, R.D., Mosconi, L., 2023. Elevated gonadotropin levels are associated with increased  
744 biomarker risk of Alzheimer's disease in midlife women. *Front. Dement.* 2, 1303256.  
745 <https://doi.org/10.3389/frdem.2023.1303256>  
746
- 747 Nestor, P.J., Fryer, T.D., Smielewski, P., Hodges, J.R., 2003. Limbic hypometabolism in  
748 Alzheimer's disease and mild cognitive impairment. *Ann. Neurol.* 54, 343–351.  
749 <https://doi.org/10.1002/ana.10669>  
750
- 751 Niwczyk, O., Grymowicz, M., Szczęsnowicz, A., Hajbos, M., Kostrzak, A., Budzik, M.,  
752 Maciejewska-Jeske, M., Bala, G., Smolarczyk, R., Męczekalski, B., 2023. Bones and  
753 hormones: interaction between hormones of the hypothalamus, pituitary, adipose tissue and  
754 bone. *Int. J. Mol. Sci.* 24, 6840. <https://doi.org/10.3390/ijms24076840>  
755
- 756 O'Brien, J., Ames, D., Schweitzer, I., Colman, P., Desmond, P., Tress, B., 1996. Clinical and  
757 magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in  
758 depression and Alzheimer's disease. *Br. J. Psychiatry.* 168, 679-687.  
759 <https://doi.org/10.1192/bjp.168.6.679>  
760
- 761 Ofori, E., Solis, A., Punjani, N., 2024. The association among hypothalamic subunits,  
762 gonadotropic and sex hormone plasmas levels in Alzheimer's disease. *Brain Sci.* 14, 276.  
763 <https://doi.org/10.3390/brainsci14030276>  
764
- 765 Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D.,  
766 Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw,  
767 J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S.,  
768 McGuinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., Moher,  
769 D., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic  
770 reviews. *BMJ.* 372, n71. <https://doi.org/10.1136/bmj.n71>  
771
- 772 Piguet, O., Petersén, A., Yin Ka Lam, B., Gabery, S., Murphy, K., Hodges, J.R., Halliday,  
773 G.M., 2011. Eating and hypothalamus changes in behavioral-variant frontotemporal  
774 dementia. *Ann. Neurol.* 69, 312–319. <https://doi.org/10.1002/ana.22244>  
775
- 776 Popp, J., Wolfsgruber, S., Heuser, I., Peters, O., Hüll, M., Schröder, J., Möller, H.-J.,  
777 Lewczuk, P., Schneider, A., Jahn, H., Luckhaus, C., Perneczky, R., Frölich, L., Wagner, M.,

- 778 Maier, W., Wiltfang, J., Kornhuber, J., Jessen, F., 2015. Cerebrospinal fluid cortisol and  
779 clinical disease progression in MCI and dementia of Alzheimer's type. *Neurobiol. Aging.* 36,  
780 601–607. <https://doi.org/10.1016/j.neurobiolaging.2014.10.031>  
781
- 782 Purba, J.S., Hofman, M.A., Swaab, D.F., 1994. Decreased number of oxytocin-  
783 immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's  
784 disease. *Neurology.* 44, 84–89. <https://doi.org/10.1212/wnl.44.1.84>  
785
- 786 Raadsheer, F.C., van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J.,  
787 Swaab, D.F., 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular  
788 nucleus of patients with Alzheimer's disease and depression. *Am. J. Psychiatry.* 152, 1372–  
789 1376. <https://doi.org/10.1176/ajp.152.9.1372>  
790
- 791 Saper, C.B., German, D.C., 1987. Hypothalamic pathology in Alzheimer's disease. *Neurosci.*  
792 *Lett.* 74, 364–370. [https://doi.org/10.1016/0304-3940\(87\)90325-9](https://doi.org/10.1016/0304-3940(87)90325-9)  
793
- 794 Saper, C.B., Scammell, T.E., Lu, J., 2005. Hypothalamic regulation of sleep and circadian  
795 rhythms. *Nature.* 437, 1257–1263. <https://doi.org/10.1038/nature04284>  
796
- 797 Schultz, C., Braak, H., Braak, E., 1996. A sex difference in neurodegeneration of the human  
798 hypothalamus. *Neurosci. Lett.* 212, 103–106. [https://doi.org/10.1016/0304-3940\(96\)12787-7](https://doi.org/10.1016/0304-3940(96)12787-7)  
799
- 800 Schultz, C., Ghebremedhin, E., Braak, E., Braak, H., 1999. Sex-dependent cytoskeletal  
801 changes of the human hypothalamus develop independently of Alzheimer's disease. *Exp.*  
802 *Neurol.* 160, 186–193. <https://doi.org/10.1006/exnr.1999.7185>  
803
- 804 Shan, L., Bossers, K., Unmehopa, U., Bao, A.-M., Swaab, D.F., 2012. Alterations in the  
805 histaminergic system in Alzheimer's disease: a postmortem study. *Neurobiol. Aging.* 33,  
806 2585–2598. <https://doi.org/10.1016/j.neurobiolaging.2011.12.026>  
807
- 808 Shapiro, N.L., Todd, E.G., Billot, B., Cash, D.M., Iglesias, J.E., Warren, J.D., Rohrer, J.D.,  
809 Bocchetta, M., 2022. In vivo hypothalamic regional volumetry across the frontotemporal  
810 dementia spectrum. *Neuroimage. Clin.* 35, 103084.  
811 <https://doi.org/10.1016/j.nicl.2022.103084>  
812
- 813 Smith, M.A., Bowen, R.L., Nguyen, R.Q., Perry, G., Atwood, C.S., Rimm, A.A., 2018.  
814 Putative gonadotropin-releasing hormone agonist therapy and dementia: an application of



815 Medicare hospitalization claims data. *J. Alzheimers. Dis.* 63, 1269–1277.  
816 <https://doi.org/10.3233/JAD-170847>  
817  
818 Soneson, C., Fontes, M., Zhou, Y., Denisov, V., Paulsen, J.S., Kirik, D., Petersén, A.,  
819 Huntington Study Group PREDICT-HD investigators, 2010. Early changes in the  
820 hypothalamic region in prodromal Huntington disease revealed by MRI analysis. *Neurobiol.*  
821 *Dis.* 40, 531–543. <https://doi.org/10.1016/j.nbd.2010.07.013>  
822  
823 Soysal, P., Tan, S.G., Rogowska, M., Jawad, S., Smith, L., Veronese, N., Tsiptsios, D.,  
824 Tsamakis, K., Stewart, R., Mueller, C., 2021. Weight loss in Alzheimer's disease, vascular  
825 dementia and dementia with Lewy bodies: impact on mortality and hospitalization by  
826 dementia subtype. *Int. J. Geriatr. Psychiatry.* 37. <https://doi.org/10.1002/gps.5659>  
827  
828 Tang, X., Song, Z.-H., Wang, D., Yang, J., Augusto Cardoso, M., Zhou, J.-B., Simó, R., 2021.  
829 Spectrum of thyroid dysfunction and dementia: a dose-response meta-analysis of 344,248  
830 individuals from cohort studies. *Endocr. Connect.* 10, 410–421. [https://doi.org/10.1530/EC-](https://doi.org/10.1530/EC-21-0047)  
831 [21-0047](https://doi.org/10.1530/EC-21-0047)  
832  
833 Toledo, J.B., Toledo, E., Weiner, M.W., Jack, C.R., Jagust, W., Lee, V.M.Y., Shaw, L.M.,  
834 Trojanowski, J.Q., Alzheimer's Disease Neuroimaging Initiative, 2012. Cardiovascular risk  
835 factors, cortisol, and amyloid- $\beta$  deposition in Alzheimer's disease neuroimaging initiative.  
836 *Alzheimers. Dement.* 8, 483–489. <https://doi.org/10.1016/j.jalz.2011.08.008>  
837  
838 Tse, N.Y., Bocchetta, M., Todd, E.G., Devenney, E.M., Tu, S., Caga, J., Hodges, J.R.,  
839 Halliday, G.M., Irish, M., Kiernan, M.C., Piguet, O., Rohrer, J.D., Ahmed, R.M., 2023. Distinct  
840 hypothalamic involvement in the amyotrophic lateral sclerosis-frontotemporal dementia  
841 spectrum. *Neuroimage. Clin.* 37, 103281. <https://doi.org/10.1016/j.nicl.2022.103281>  
842  
843 Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., 2021. The  
844 Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-  
845 analyses. [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) (accessed 3rd Sept  
846 2024).  
847  
848 Westwood, A.J., Beiser, A., DeCarli, C., Harris, T.B., Chen, T.C., He, X., Roubenoff, R.,  
849 Pikula, A., Au, R., Braverman, L.E., Wolf, P.A., Vasan, R.S., Seshadri, S., 2014. Insulin-like  
850 growth factor-1 and risk of Alzheimer dementia and brain atrophy. *Neurology.* 82, 1613–  
851 1619. <https://doi.org/10.1212/WNL.0000000000000382>

852

853 Whitwell, J.L., Weigand, S.D., Shiung, M.M., Boeve, B.F., Ferman, T.J., Smith, G.E.,  
854 Knopman, D.S., Petersen, R.C., Benarroch, E.E., Josephs, K.A., Jack, C.R., Jr, 2007. Focal  
855 atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.  
856 *Brain*. 130, 708–719. <https://doi.org/10.1093/brain/awl388>

857

858 Woolley, J.D., Khan, B.K., Natesan, A., Karydas, A., Dallman, M., Havel, P., Miller, B.L.,  
859 Rankin, K.P., 2014. Satiety-related hormonal dysregulation in behavioral variant  
860 frontotemporal dementia. *Neurology*. 82, 512–520.  
861 <https://doi.org/10.1212/WNL.000000000000106>

862

863 Xie, C., Wang, C., Luo, H., 2023. Increased risk of osteoporosis in patients with cognitive  
864 impairment: a systematic review and meta-analysis. *BMC Geriatr*. 23, 1–10.  
865 <https://doi.org/10.1186/s12877-023-04548-z>

866


867 Yasui, K., Inoue, Y., Kanbayashi, T., Nomura, T., Kusumi, M., Nakashima, K., 2006. CSF  
868 orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear  
869 palsy and corticobasal degeneration. *J. Neurol. Sci*. 250, 120–123.  
870 <https://doi.org/10.1016/j.jns.2006.08.004>

871


872 Yong-Hong, L., Xiao-Dong, P., Chang-Quan, H., Bo, Y., Qing-Xiu, L., 2013. Hypothalamic-  
873 pituitary-thyroid axis in patients with Alzheimer disease (AD). *J. Investig. Med*. 61, 578–581.  
874 <https://doi.org/10.2310/JIM.0b013e318280aafb>

875


876 Zhou, H.-H., Yu, Z., Luo, L., Xie, F., Wang, Y., Wan, Z., 2021. The effect of hormone  
877 replacement therapy on cognitive function in healthy postmenopausal women: a meta-  
878 analysis of 23 randomized controlled trials. *Psychogeriatrics*. 21, 926–938.  
879 <https://doi.org/10.1111/psyg.12768>



**Figure 1.** Flowchart showing the selection of articles for the meta-analysis and secondary narrative synthesis. PET = positron emission tomography, SPECT = single-photon emission computed tomography.



**Figure 2.** Forest plot of the pooled standardised mean difference (Hedges’ g) showing that subjects with Alzheimer’s disease (AD) had a significantly smaller hypothalamus compared to healthy controls.



**Figure 3.** Funnel plot of included studies demonstrating no suggestion of publication bias.

**Table 1.** Summary of studies included in the data synthesis. ACE-R = Addenbrooke’s cognitive examination revised, AD = Alzheimer’s disease, Ant-Inf = anterior-inferior subunit, Ant-Sup = anterior-superior subunit, APEHQ = Appetite and eating habits questionnaire, BMI = body mass index, CBI = Cambridge behavioural inventory, DLB = dementia with Lewy bodies, FSH = follicle-stimulating hormone, Inf-Tub = inferior-tubular subunit, LH = lutenising hormone, M = mini-mental state examination, 3MS = modified mini-mental state examination, MPRAGE = magnetization prepared rapid gradient echo, NS = not significant, OSHy-X = open source hypothalamic-fornix atlas and tool, Post – posterior subunit, RBDSQ-K = Rapid eye movement behaviour disorder screening questionnaire Korean, ROIs = region of interests, SD = standard deviation, SPGR = spoiled gradient echo, Sup-Tub = superior-tubular subunit, T = Tesla, TIV = total intracranial volume, VBM = voxel based morphometry, %W = % women.

| Study<br>Author<br>(year) | Demographics<br>Group (n)<br>Age, %W<br>Cognition: M, 3MS, or ACE-R                                   | MRI characteristics<br>Field strength<br>Sequence<br>Voxel or slice size<br>Analysis method | Risk of<br>bias | Hypothalamic volume<br>Mean (SD)   | Mean difference AD<br>compared to controls<br>(%) | Clinical correlations |
|---------------------------|---|---|-----------------|--|---|-----------------------|
| Grundman<br>(1996)        | AD (58)<br>71.8y, 50%W, M:19.2<br><br>Controls (16)<br>72.5y, 69%W, M:28.9                            | 1.5T<br>Multiple-echo sequence.<br>Slices: 5mm.<br>Manual ROIs.                             | Low             | AD<br>0.12% (0.05%) of TIV<br><br>Controls<br>0.17% (0.04%) of TIV   | -29.41%   | BMI: r=0.14 (NS)      |
| Baron<br>(2001)           | AD (19)<br>73y, 58%W, M: 22.4<br><br>Controls (16)<br>66y, 56%W, M not reported                       | 1.5T<br>T1 (SPGR) sequence<br>Voxels: 2mm <sup>3</sup><br>VBM                               | Moderate        | Gray matter loss in anterior<br>hypothalamus in AD<br>compared to controls.  | Not measured.                                     | Not measured.         |
| Callen<br>(2001)          | AD (40)<br>69.1y, 50%W, M:19.5<br><br>Controls (40)<br>70.4y, 50%W, M:28.5                            | 1.5T<br>T1 sequence.<br>Voxels: 0.634 mm <sup>3</sup> .<br>Manual ROIs.                     | Low             | AD<br>266.5 (54.3) mm <sup>3</sup><br><br>Controls<br>298.6 (43.2) mm <sup>3</sup>                                   | -10.75%   | Not measured          |
| Callen<br>(2004)          | Same as Callen (2001).  | Same as Callen (2001).  | Low             | Same as Callen (2001).   | Same as Callen (2001).                            | Sex (men<women)       |
| Whitwell<br>(2007)        | AD (73)<br>76y, 24%W, M:21<br><br>DLB (73)<br>73y, 24%W, M:22<br><br>Controls (73)<br>74y, 24%W, M:29 | 1.5T<br>T1 (SPGR) sequence<br>Slices: 1.6mm<br>VBM  | Low             | Grey matter loss in the<br>hypothalamus in DLB<br>compared to controls.  | Not measured.                                     | Not measured.         |
| Hall<br>(2008)            | AD (26)<br>83.2y, 61%W, 3MS:76.7<br><br>Controls (127)<br>77.3y, 54%W, 3MS:96.9                       | 1.5T<br>T1 (SPGR) sequence<br>Voxels: 1 mm <sup>3</sup><br>VBM                              | Moderate        | Grey matter loss in the<br>hypothalamus in AD<br>compared to controls, and<br>in subjects who later<br>developed AD. | Not measured.                                     | Not measured.         |

Table 1 continued.

| Study Author (year) | Demographics Group (n)<br>Age, %W<br>Cognition: M or ACE-R                                    | MRI characteristics Field strength<br>Sequence<br>Voxel or slice size<br>Analysis method   | Risk of bias | Hypothalamic volume Mean (SD)  | Mean difference AD compared to controls (%)  | Clinical correlations   |
|---------------------|---|--|--------------|--|--|---|
| Loskutova (2010)    | <u>AD (63)</u><br>74.4y, 62%W, M:26.1<br><br><u>Controls (55)</u><br>73.2y, 58%W, M:29.5      | 3T<br>T1 (MPRAGE) sequence<br>Voxels:1 mm <sup>3</sup> .<br>VBM with small volume correction.  | Moderate     | <u>AD</u><br>570 (100) mm <sup>3</sup><br><br><u>Controls</u><br>650 (120) mm <sup>3</sup>           | -12.31%  | Bone mineral density: r = 0.34, (p = 0.007)   |
| Ahmed (2015)        | <u>AD (30)</u><br>68y, 27%W, ACE-R: 68<br><br><u>Controls (23)</u><br>72y, 52%W, ACE-R: 94    | Field strength not stated.<br>T1 sequence<br>Voxels: 1 mm <sup>3</sup> .<br>Manual ROIs.   | Moderate     | <u>AD</u><br>0.138% (0.02%) of TIV.<br><br><u>Controls</u><br>0.137% (0.013%) of TIV                 | +0.73%   | CBI (NS), APEHQ (NS)<br>BMI (NS)<br>Leptin (NS)<br>Cholecystokinin (NS)<br>Peptide YY (NS)<br>Oxytocin (NS)<br>Ghrelin (NS)<br>Agouti-related peptide (NS)                  |
| Kim (2016)          | <u>AD (23)</u><br>71.6y, 61%W, M:20,1<br><br><u>Controls (36)</u><br>72.9y, 47%W, M:29.3      | 3T<br>T1 (SPGR) sequence.<br>Slices: 1mm.<br>VBM   | Low          | Not reported.  | Not reported.  | RBDSQ-K score (trend only).   |
| Billot (2020)       | <u>AD (134)</u><br>76.0y, 46%W<br><br><u>Controls (183)</u><br>72.9y, 49%W<br>M not reported. | T1<br>Sequence not reported.<br>Voxels: 1mm <sup>3</sup> .<br>Automated segmentation using Freesurfer.   | High         | Not reported.  | <u>Cohen's d</u><br>Hypothalamus (0.96)<br>Ant-Sup (1.16)<br>Ant-Inf (0.99)<br>Sup-Tub (0.60)<br>Inf-Tub (0.34)<br>Post (0.94) | Not reported.   |
| Chang (2022)        | <u>AD (167)</u><br>68y, 50%W<br><br><u>Controls (527)</u><br>68y, 58%W<br>M not reported      | 3T or 7T<br>T1 (MPRAGE or accelerated inversion recovery SPGR) sequence<br>Voxels: 1mm <sup>3</sup> or 0.9 mm <sup>3</sup> .<br>Automated segmentation using OSHy-X. | High         | <u>AD</u><br>746.62 mm <sup>3</sup> (121.29)<br><br><u>Controls</u><br>771.2 mm <sup>3</sup> (97.88) | -3.19%   | BMI (NS)<br>Sex (NS)  |
| Ofori (2024)        | <u>AD (96)</u><br>75.1y, 45%W, M:21.3<br><br><u>Controls (54)</u><br>75.3y, 48%W, M:29.1      | 1.5T<br>T1 (MPRAGE) sequence.<br>Automatic segmentation using Freesurfer.  | Moderate     | <u>AD</u><br>0.034% (0.0039%)<br><br><u>Controls</u><br>0.036% (0.0037%)                             | -5.56%   | Sex (men<women)<br><br><u>In women only:</u><br>FSH and Inf-Tub. (R <sup>2</sup> =0.11)<br>LH and Inf-Tub. (R <sup>2</sup> =0.11)<br>Testosterone (NS)<br>Progesterone (NS) |